Cushing disease

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:96253OMIM:219090E24.0D35.2
Who is this for?
Show terms as
2FDA treatments9Active trials45Specialists8Treatment centers2Financial resources

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Also known as:

Clinical phenotype terms— hover any for plain English:

PlethoraHP:0001050Increased circulating ACTH levelHP:0003154Increased body weightHP:0004324Proximal amyotrophyHP:0007126Adrenal hyperplasiaHP:0008221Intra-oral hyperpigmentationHP:0010284
Orphanet ↗OMIM ↗NORD ↗

FDA & Trial Timeline

10 events
Apr 2026FET PET/CT Imaging To Localize Pituitary Adenomas In Cushing Disease

Mayo Clinic — EARLY_PHASE1

TrialNOT YET RECRUITING
Mar 2026DDAVP for Pituitary Adenoma

National Institute of Neurological Disorders and Stroke (NINDS) — NA

TrialRECRUITING
Oct 2025Use of [18F]FET PET-MRI to Improve Detection of Pituitary Adenomas in Cushing's Disease

University Hospital, Basel, Switzerland — NA

TrialENROLLING BY INVITATION
Jan 2025Fimepinostat, Combination HDAC and Pi3-kinase Inhibitor Tumor-Directed Therapy for Cushing Disease

University of California, Los Angeles — PHASE2

TrialRECRUITING
Jun 2024Evaluation of Intraoperative Contrast Enhanced Ultrasound for the Identification of Pituitary Adenoma in Cushing's Disease Compared to Other Pituitary Tumors

Mayo Clinic

TrialRECRUITING
Nov 2023Evaluation of Positron Emission Tomography (PET) With [18F]FET for the Detection of ACTH-Secreting Corticotroph Pituitary Neuroendocrine Tumors.

Hospices Civils de Lyon

TrialRECRUITING
Dec 2020Postoperative Thrombosis Prevention in Patients With CD

Huashan Hospital — NA

TrialACTIVE NOT RECRUITING
Mar 2020

Isturisa: FDA approved

ISTURISA is a cortisol synthesis inhibitor indicated for the treatment of adult patients with Cushing®s disease for whom pituitary surgery is not an option or has not been curative.

FDAcompleted
Jul 2019Discriminant Capacity and Thresholds of Salivary Cortisol in Chemiluminescence in the Diagnosis of Hypercorticisms

Centre Hospitalier Universitaire de Nīmes

TrialACTIVE NOT RECRUITING
Mar 2019Long-Term Follow-Up of Survivors of Pediatric Cushing Disease

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

TrialRECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

2 available

Isturisa

osilodrostat· Recordati Rare Diseases, IncOrphan Drug

ISTURISA is a cortisol synthesis inhibitor indicated for the treatment of adult patients with Cushing�s disease for whom pituitary surgery is not an option or has not been curative.

Signifor

pasireotide· Novartis Pharmaceuticals CorporationOrphan Drug

SIGNIFOR� LAR is indicated for the treatment of patients with Cushing�s disease for whom pituitary surgery is not an option or has not been curative.

Clinical Trials

9 recruitingView all trials with filters →
Phase 22 trials
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
Phase 2
Actively Recruiting
PI: Shlomo Melmed, MD (Cedars-Sinai Medical Center) · Sites: Los Angeles, California · Age: 1899 yrs
Fimepinostat, Combination HDAC and Pi3-kinase Inhibitor Tumor-Directed Therapy for Cushing Disease
Phase 2
Actively Recruiting
· Sites: Los Angeles, California · Age: 1899 yrs
N/A3 trials
DDAVP for Pituitary Adenoma
N/A
Actively Recruiting
PI: Prashant Chittiboina, M.D. (National Institute of Neurological Disorders and S) · Sites: Bethesda, Maryland · Age: 899 yrs
Use of [18F]FET PET-MRI to Improve Detection of Pituitary Adenomas in Cushing's Disease
N/A
Enrolling by Invitation
· Sites: Rotterdam, South Holland; Basel, Canton of Basel-City · Age: 1899 yrs
Postoperative Thrombosis Prevention in Patients With CD
N/A
Active
· Sites: Fuzhou, Fujian; Guangzhou, Guangdong +5 more · Age: 1865 yrs
Other4 trials
Evaluation of Intraoperative Contrast Enhanced Ultrasound for the Identification of Pituitary Adenoma in Cushing's Disease Compared to Other Pituitary Tumors
Actively Recruiting
PI: Ian Mark, MD (Mayo Clinic) · Sites: Rochester, Minnesota
Evaluation of Positron Emission Tomography (PET) With [18F]FET for the Detection of ACTH-Secreting Corticotroph Pituitary Neuroendocrine Tumors.
Actively Recruiting
· Sites: Bron · Age: 1899 yrs
Discriminant Capacity and Thresholds of Salivary Cortisol in Chemiluminescence in the Diagnosis of Hypercorticisms
Active
PI: David de Brauwere (CHU Nimes) · Sites: Nîmes · Age: 1899 yrs
Long-Term Follow-Up of Survivors of Pediatric Cushing Disease
Actively Recruiting
PI: Deborah P Merke, M.D. (Eunice Kennedy Shriver National Institute of Child) · Sites: Bethesda, Maryland · Age: 290 yrs

Specialists

Showing 25 of 45View all specialists →
SM
Shlomo Melmed, MD
LOS ANGELES, CA
Specialist
PI on 7 active trials
JP
Jens Otto Lunde Jørgensen, Professor
Specialist
PI on 1 active trial
JP
Joseph Custodio, PhD
Specialist
PI on 1 active trial
GM
Guido Di Dalmazi, MD
Specialist
PI on 1 active trial
GP
Gudmundur Johannsson, Professor
Specialist
PI on 2 active trials2 Cushing disease publications
HP
Ho Sung Kim, MD PhD
Specialist
PI on 2 active trials
SP
Stylianos Tsagarakis, Professor
Specialist
PI on 1 active trial
AM
Anne Klibanski, MD
BOSTON, MA
Specialist
PI on 2 active trials1 Cushing disease publication
LM
Lynnette K Nieman, M.D.
BETHESDA, MD
Specialist
PI on 9 active trials
AM
Andreas Moraitis, MD
SUNNY ISLES BEACH, FL
Specialist
PI on 2 active trials
DM
Deborah P Merke, M.D.
BETHESDA, MD
Specialist
PI on 7 active trials
PM
Prashant Chittiboina, M.D.
Bethesda, Maryland
Specialist

Rare Disease Specialist

PI on 7 active trials
SP
Sophie Bensing, MD phD
Specialist
PI on 1 active trial
EP
EMILIE GARRIDO PRADALIE
Specialist
PI on 13 active trials
AM
Andreas G Moraitis, MD
SUNNY ISLES BEACH, FL
Specialist
PI on 2 active trials1 Cushing disease publication
SP
Stafford Lightman, Professor
Specialist
PI on 1 active trial
CB
Claire BRIET
Specialist
PI on 1 active trial3 Cushing disease publications
LP
Liudmila Rozhinskaya, MD, PhD
Specialist
PI on 1 active trial
AP
Antoine Tabarin, Pr
Specialist
PI on 2 active trials
IM
Irina Bancos, MD
ROCHESTER, MN
Specialist
PI on 3 active trials1 Cushing disease publication
FM
Fredric J Cohen, MD
Specialist
PI on 1 active trial
BP
Bruno Feve, PhD
Specialist
PI on 1 active trial
MM
Mario M MALDONADO, MD
LANCASTER, CA
Specialist
PI on 1 active trial
MP
Mar Pujades-Rodriguez, PhD
Specialist
PI on 1 active trial
GM
Gabrielle Page-Wilson, MD
NEW YORK, NY
Specialist
PI on 1 active trial

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Financial Resources

2 resources
Isturisa(osilodrostat)Recordati Rare Diseases, Inc
Signifor(pasireotide)Novartis Pharmaceuticals Corporation

Travel Grants

No travel grants are currently matched to Cushing disease.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Cushing diseaseForum →

No community posts yet. Be the first to share your experience with Cushing disease.

Start the conversation →

Latest news about Cushing disease

Disease timeline:

New recruiting trial: A Trial of Lu AG13909 in Adult Participants With Cushing's Disease

A new clinical trial is recruiting patients for Cushing disease

New recruiting trial: Long-Term Follow-Up of Survivors of Pediatric Cushing Disease

A new clinical trial is recruiting patients for Cushing disease

New recruiting trial: DDAVP for Pituitary Adenoma

A new clinical trial is recruiting patients for Cushing disease

New recruiting trial: Evaluation of Intraoperative Contrast Enhanced Ultrasound for the Identification of Pituitary Adenoma in Cushing's Disease Compared to Other Pituitary Tumors

A new clinical trial is recruiting patients for Cushing disease

New recruiting trial: Evaluation of Positron Emission Tomography (PET) With [18F]FET for the Detection of ACTH-Secreting Corticotroph Pituitary Neuroendocrine Tumors.

A new clinical trial is recruiting patients for Cushing disease

New recruiting trial: Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease

A new clinical trial is recruiting patients for Cushing disease

New recruiting trial: Fimepinostat, Combination HDAC and Pi3-kinase Inhibitor Tumor-Directed Therapy for Cushing Disease

A new clinical trial is recruiting patients for Cushing disease

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Cushing disease

Are there clinical trials for Cushing disease?

Yes — 9 recruiting clinical trials are currently listed for Cushing disease on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat Cushing disease?

25 specialists and care centers treating Cushing disease are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.

What treatment and support options exist for Cushing disease?

3 patient support programs are currently tracked on UniteRare for Cushing disease. See the treatments and support programs sections for copay assistance, eligibility, and contact details.